Le Registre des lobbyistes
| Objets | Détails | Catégories |
|---|---|---|
|
Santé
|
Bill S-201, National Framework on Sickle Cell Disease Act, respecting provisions outlined in Section 2, subsections (a), (b), (e), and (i).
|
Proposition législative, Projet de loi ou résolution
|
|
Santé
|
Common Drug Review, as it relates to health technology assessments and drug product reimbursement recommendations.
|
Politique ou Programme
|
|
Budget, Développement économique, Relations fédérales-provinciales, Santé
|
Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases.
|
Politique ou Programme
|
|
Budget, Santé
|
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
|
Politique ou Programme
|
|
Budget, Relations fédérales-provinciales, Santé
|
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals.
|
Politique ou Programme
|
|
Développement économique, Santé, Propriété intellectuelle
|
Innovation, Science and Economic Development Canada Innovation and Skills Strategy and other government policies and programs related to incentivizing research and development activities in Canada.
|
Politique ou Programme
|
|
Relations fédérales-provinciales, Santé
|
Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
|
Règlement
|
Vertex is a global biotechnology company that discovers, develops and commercializes innovative medicines. We strive to improve the lives of patients suffering from rare and chronic disorders and are currently investing in multiple ongoing research programs targeting serious and life-threatening diseases.
Michael Siauw, General Manager – Canada
Adresse :
20 Bay Street
unit 1520
Toronto, ON M5J 2N8
Canada
Numéro de téléphone :
647-790-1600
Vertex Pharmaceuticals (Canada) Incorporated ne possède aucune filiale qui pourrait être directement intéressée au résultat de l'engagement